Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.51 |
| ▸ | CTSD | P07339 | 15/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924183 | 1.00 | BACE1 (0.51) | BACE1CTSDBACE2HPGD | |
| SCHEMBL924181 | 1.00 | BACE1 (0.51) | BACE1CTSDBACE2HPGD | |
| SCHEMBL2607309 | 0.85 | BACE1 (0.74) | BACE1CTSDBACE2 | |
| SCHEMBL2607261 | 0.85 | BACE1 (0.71) | BACE1CTSDBACE2 | |
| SCHEMBL2607059 | 0.79 | BACE1 (0.68) | BACE1CTSDBACE2 | |
| SCHEMBL2607257 | 0.78 | BACE1 (0.67) | BACE1CTSDBACE2 | |
| SCHEMBL3167770 | 0.77 | BACE1 (0.72) | BACE1CTSDBACE2 | |
| SCHEMBL3167755 | 0.77 | BACE1 (0.72) | BACE1CTSDBACE2 | |
| SCHEMBL13315909 | 0.76 | BACE1 (0.81) | BACE1CTSDBACE2 | |
| SCHEMBL14450737 | 0.76 | BACE1 (0.81) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163766-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7872009-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1954693-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007062007-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | BACE1 1/4885CTSD 152/4885BACE2 2/4885 |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | BACE1 1/4885CTSD 152/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.